RecruitingNot ApplicableNCT06584123
Molecular Pituitary Imaging Using 18F-FET PET
Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)
Sponsor
University of Cambridge
Enrollment
20 participants
Start Date
Sep 3, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria4
- Participant is willing and able to give informed consent for participation in the study
- Male or female, age 18 or above
- Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings
- Previous 11C-Met-PET/CT
Exclusion Criteria5
- Inability to give informed consent
- Pregnancy or suspected pregnancy
- Inability to lie supine for 30-60 minutes
- Patient body habitus above scanner dimensions
- Known allergy to intravenous radiographic contrast agents
Interventions
DIAGNOSTIC_TEST18F-Fluoro-ethyl-tyrosine (FET) PET
18F-Fluoro-ethyl-tyrosine PET study of the pituitary
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06584123
Related Trials
DDAVP for Pituitary Adenoma
NCT045695911 location
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
NCT074568781 location
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
NCT073353151 location
Effect of Foot Bath on Anxiety and Physiological Parameters
NCT072475261 location
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
NCT040817011 location